Clonal Hematopoiesis is Associated with Risk of Incident, Seropositive Rheumatoid Arthritis
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Objectives:
Clonal hematopoiesis (CH), defined by acquired mutations in hematopoietic stem cells, has been linked to many inflammatory diseases of aging. We investigated whether CH subtypes such as clonal hematopoiesis of indeterminate potential (CHIP) and mosaic chromosomal alteration (mCA) are associated with the risk of incident rheumatoid arthritis (RA) and whether complement modifies these associations.
Methods:
CHIP was ascertained in NIH AllOfUs, Vanderbilt BioVU, and the UKBiobank; mCA was detected in UKBiobank. A consistent phenotyping algorithm was applied across biobanks to identify seropositive RA (SPRA) and seronegative RA (SNRA). Age-scale survival models assessed the effect of CH on risk of incident RA. Effect modification was tested with interaction models with genetically predicted complement protein levels.
Results:
Among 612,989 eligible participants, 30,840 had CHIP, 2,110 had incident SPRA, and 1,310 had incident SNRA. CHIP was associated with an increased risk of incident SPRA (HR 1.29; CI 1.05-1.57; p =1.3×10 -2 ) driven primarily by DNMT3A -mutated CHIP (HR 1.42, CI 1.1-1.82, p =7.1×10 -3 ) but no risk of SNRA. In UKBiobank, autosomal mCA and mosaic loss of Y (mLOY) were associated with an increased risk of incident SPRA (HR 2.12 and 2.85; CI 1.18-3.8 and 1.57-5.19; p =1.2×10 -2 and 6.1×10 -4 ), but no risk of SNRA. Higher genetically predicted levels of C1r and C1s attenuated the CHIP-SPRA association.
Conclusions:
DNMT3A -CHIP, autosomal mCA and mLOY are novel risk factors for incident SPRA but not SNRA, supporting a serostatus-specific link between somatic mutation in epigenetic regulators and RA, with the classical complement pathway as a potential modifier of this risk.
